Lipocine's LPCN 1144 for NASH Met Topline Endpoint in Phase 2

 Histological Analysis Demonstrates Treatment Potential of LPCN 1144 in NASH

- Both LPCN 1144 treatment arms met with statistical significance the pre-specified histology based regulatory endpoint of NASH resolution with no worsening of fibrosis

- Treatment effect observed on fibrosis improvement needs confirmation in a larger study

- Changes in key liver enzymes and body composition support beneficial treatment effects of LPCN 1144

- LPCN 1144 was well tolerated with an overall safety profile comparable to placebo

- Positive topline results support LPCN 1144 development for regulatory approval

-- Conference Call Scheduled for 8:30 a.m. ET today

Management will host a conference call and webcast today at 8:30 a.m. Eastern time to discuss LPCN 1144 Phase 2 LiFT clinical study key secondary endpoint topline results. To participate in the conference call, please dial 1-877-451-6152 from the U.S. or 1-201-389-0879 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until September 1, 2021, by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 from outside the U.S. and entering conference ID #13722634. Those interested in listening to the conference call live via the internet may do so by using the following link: http://public.viavid.com/index.php?id=146385. An archive of the webcast will also be available on the webcast page of the Company's website for 90 days.

https://finance.yahoo.com/news/lipocines-lpcn-1144-met-non-103000283.html